- Home
- HRMY vs CC Comparison
HRMY vs CC Comparison
Compare HRMY & CC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CC
- Stock Information
- Founded
- HRMY 2017
- CC 2014
- Country
- HRMY United States
- CC United States
- Employees
- HRMY N/A
- CC N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CC Major Chemicals
- Sector
- HRMY Health Care
- CC Industrials
- Exchange
- HRMY Nasdaq
- CC Nasdaq
- Market Cap
- HRMY 2.1B
- CC 2.1B
- IPO Year
- HRMY 2020
- CC N/A
- Fundamental
- Price
- HRMY $32.29
- CC $17.09
- Analyst Decision
- HRMY Strong Buy
- CC Buy
- Analyst Count
- HRMY 9
- CC 8
- Target Price
- HRMY $55.33
- CC $17.25
- AVG Volume (30 Days)
- HRMY 678.1K
- CC 3.0M
- Earning Date
- HRMY 10-28-2025
- CC 11-03-2025
- Dividend Yield
- HRMY N/A
- CC 2.05%
- EPS Growth
- HRMY 58.41
- CC N/A
- EPS
- HRMY 3.10
- CC N/A
- Revenue
- HRMY $772,527,000.00
- CC $5,850,000,000.00
- Revenue This Year
- HRMY $20.09
- CC $5.12
- Revenue Next Year
- HRMY $16.86
- CC $4.79
- P/E Ratio
- HRMY $10.42
- CC N/A
- Revenue Growth
- HRMY 17.74
- CC 0.62
- 52 Week Low
- HRMY $26.47
- CC $9.13
- 52 Week High
- HRMY $41.61
- CC $22.38
- Technical
- Relative Strength Index (RSI)
- HRMY 30.41
- CC 54.17
- Support Level
- HRMY $31.61
- CC N/A
- Resistance Level
- HRMY $37.05
- CC $17.03
- Average True Range (ATR)
- HRMY 1.18
- CC 0.59
- MACD
- HRMY -0.59
- CC -0.52
- Stochastic Oscillator
- HRMY 10.19
- CC 97.85
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.